June 23 (Reuters) - Leap Therapeutics Inc LPTX.O:
LEAP THERAPEUTICS REPORTS UPDATED CLINICAL DATA FROM SIREXATAMAB COLORECTAL CANCER STUDY AND ANNOUNCES EXPLORATION OF STRATEGIC ALTERNATIVES
LEAP THERAPEUTICS INC - TO REDUCE WORKFORCE BY 75%
LEAP THERAPEUTICS INC - TO EXPLORE SALE OR PARTNERSHIP FOR SIREXATAMAB AND FL-501
LEAP THERAPEUTICS INC - ESTIMATES $3.2 MILLION COST FOR WORKFORCE REDUCTION
Source text: ID:nPn1vbpFCa
Further company coverage: LPTX.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.